PPT-Access to medicines in Europe

Médecins du monde Doctors of the World International Network François Berdougo Harm Reduction Working Group an independent international movement working across the world 78 countries both at home 169 . Médecins du monde – Doctors of the World International Network. François Berdougo – Harm Reduction Working Group.  . an . independent international movement working across. . the world (78 countries), both at home (169 . Médecins du monde – Doctors of the World International Network. François Berdougo – Harm Reduction Working Group.  . an . independent international movement working across. . the world (78 countries), both at home (169 . –. lessons from HIV. EPIP, 5 September 2017, Bordeaux. . Ellen ‘t Hoen, LLM. University Medical Centre Groningen, Global Health Unit. @. ellenthoen. www.medicineslawandpolicy.org. Brief history. Stops AIDS National Gathering . 1st November 2014. Aliénor Devali. ère. Health. Action International (HAI) Europe. This document arises from HAI Europe’s Operating Grant 2014, which has received funding from the . Gilles . Forte. Coordinator, Policy, Access and Use Team. Essential . Medicines . and . Health Products. . WHO . mandate . within the . International . Drug Control Conventions. 1961 . Single Convention on Narcotic Drugs (Article 3). WHO EMP and NVI Departments. Access to NCD essential medicines . on the global agenda. Access to chronic disease medicines is required for the fulfilment of MDG8. Governments, in collaboration with the private sector, should give greater priority to treating chronic diseases and improving the accessibility of medicines to treat them (MDG Report 2009). sustainably and equitably financed. Summary Discussion…1. What information needed to estimate cost program of medicines benefits. MBM . Ned to estimate the total economic cost of setting up a MBM program. Draft concept for a new World Bank-led multi-stakeholder initiative . August 2014, Andreas . Seiter. What is AIM 2030?. An initiative to maximize access to innovative medicines for priority diseases in low- and middle income countries (LMICs). Dr Cécile . Macé. . WHO EMP , Mr Arne-Petter . Sanne. WHO MND, . Mr . Ajuebor. Onyema WHO MND. NCD Programme Managers Seminar. 4 June 2014. Access to NCD essential medicines . on the global agenda. Case Management. George Jagoe . EVP, Access & Product Management, MMV. . . The access team at MMV is heavily focused on the needs of control today. 4. Achieving patient impact means addressing many hurdles to access. The overall share of the total health budget dedicated to cancer care has remained stable over the past 20 years.. Hofmarcher. , T et al. (2019) Comparator Report on Cancer in Europe 2019 - Disease Burden, Costs and Access to Medicines. IHE Report 2019:7. IHE: Lund, Sweden. For further information, please follow:  . how . the pandemic has influenced the disease burden. Bengt . Jönsson. Professor emeritus, Stockholm School of Economics. Wednesday, 1 July 2020 – 16.30-19.00 CET (online event. ). Launch of the European Parliament  . Basic enquiry answering. September . 2016. Session aims. Increase awareness of the Medicines Information (MI) services. UK. Wales. Increase awareness of the questions to ask an enquirer. Have practical experience using some resources which will be... Dr. Richard Torbett. Chief Economist, EFPIA. China/ EU Pharmaceutical Industry Forum. Shanghai, . 16 May 2015. Policy debate on health in recent years has been dominated by cost containment. Health & Growth.